WO2006051704A1 - イミン化合物 - Google Patents
イミン化合物 Download PDFInfo
- Publication number
- WO2006051704A1 WO2006051704A1 PCT/JP2005/019977 JP2005019977W WO2006051704A1 WO 2006051704 A1 WO2006051704 A1 WO 2006051704A1 JP 2005019977 W JP2005019977 W JP 2005019977W WO 2006051704 A1 WO2006051704 A1 WO 2006051704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- halogen atom
- substituted
- alkoxy
- Prior art date
Links
- 150000002466 imines Chemical class 0.000 title claims abstract description 65
- 125000005843 halogen group Chemical group 0.000 claims abstract description 250
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 177
- 125000003118 aryl group Chemical group 0.000 claims abstract description 139
- 150000001875 compounds Chemical class 0.000 claims abstract description 120
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 92
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 230000036407 pain Effects 0.000 claims abstract description 11
- 208000002193 Pain Diseases 0.000 claims abstract description 10
- 239000003537 cannabinoid receptor agonist Substances 0.000 claims abstract description 7
- 229940121376 cannabinoid receptor agonist Drugs 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 230000003449 preventive effect Effects 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims description 399
- -1 1, 1-dioxothiolanyl group Chemical group 0.000 claims description 210
- 125000003545 alkoxy group Chemical group 0.000 claims description 190
- 125000001188 haloalkyl group Chemical group 0.000 claims description 154
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 93
- 125000003277 amino group Chemical group 0.000 claims description 91
- 125000004122 cyclic group Chemical group 0.000 claims description 88
- 239000000126 substance Substances 0.000 claims description 84
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 71
- 125000004104 aryloxy group Chemical group 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 66
- 150000003839 salts Chemical class 0.000 claims description 65
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 48
- 125000002252 acyl group Chemical group 0.000 claims description 44
- 125000003342 alkenyl group Chemical group 0.000 claims description 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 37
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 37
- 229940044601 receptor agonist Drugs 0.000 claims description 34
- 239000000018 receptor agonist Substances 0.000 claims description 34
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 33
- 125000004414 alkyl thio group Chemical group 0.000 claims description 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
- 125000004429 atom Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000004423 acyloxy group Chemical group 0.000 claims description 20
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 8
- 125000005543 phthalimide group Chemical group 0.000 claims description 8
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000005110 aryl thio group Chemical group 0.000 claims description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 5
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000005544 phthalimido group Chemical group 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 125000004149 thio group Chemical group *S* 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000001769 aryl amino group Chemical group 0.000 claims 4
- 230000001272 neurogenic effect Effects 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 125000003106 haloaryl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 59
- 239000002904 solvent Substances 0.000 description 57
- 239000000243 solution Substances 0.000 description 47
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 35
- 238000004519 manufacturing process Methods 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 238000002844 melting Methods 0.000 description 28
- 230000008018 melting Effects 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 16
- 241000233855 Orchidaceae Species 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 125000000714 pyrimidinyl group Chemical group 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000004898 kneading Methods 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 229910052783 alkali metal Inorganic materials 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- UHMUBYIIPNQHGD-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC(C(F)(F)F)=C1F UHMUBYIIPNQHGD-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000005605 benzo group Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 235000011181 potassium carbonates Nutrition 0.000 description 6
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 5
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 5
- 229910052808 lithium carbonate Inorganic materials 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 5
- 235000015497 potassium bicarbonate Nutrition 0.000 description 5
- 239000011736 potassium bicarbonate Substances 0.000 description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- QSAXVGLLBJUNCE-UHFFFAOYSA-N 1-(cyclopropylmethyl)pyridin-2-imine Chemical compound N=C1C=CC=CN1CC1CC1 QSAXVGLLBJUNCE-UHFFFAOYSA-N 0.000 description 4
- XKQNWUSIHBWFBI-UHFFFAOYSA-N 5-tert-butyl-2-(cyclopropylmethyl)pyrazol-3-amine Chemical compound N1=C(C(C)(C)C)C=C(N)N1CC1CC1 XKQNWUSIHBWFBI-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 4
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 4
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 102000056693 human CNR2 Human genes 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 4
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- DQMWMUMCNOJLSI-UHFFFAOYSA-N n-carbamothioylbenzamide Chemical compound NC(=S)NC(=O)C1=CC=CC=C1 DQMWMUMCNOJLSI-UHFFFAOYSA-N 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 3
- MMYKTRPLXXWLBC-UHFFFAOYSA-N 1-bromo-2-ethoxyethane Chemical compound CCOCCBr MMYKTRPLXXWLBC-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N 1-nonene Chemical compound CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- KUGLJYVDCCITGB-UHFFFAOYSA-N 2,2,2-trifluoro-n-pyridin-2-ylacetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC=N1 KUGLJYVDCCITGB-UHFFFAOYSA-N 0.000 description 2
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- FSINTEXYAMBKEZ-UHFFFAOYSA-N 3-(cyclopropylmethyl)-4-methyl-2-[3-(trifluoromethyl)benzoyl]imino-1,3-thiazole-5-carboxylic acid Chemical compound C1CC1CN1C(C)=C(C(O)=O)SC1=NC(=O)C1=CC=CC(C(F)(F)F)=C1 FSINTEXYAMBKEZ-UHFFFAOYSA-N 0.000 description 2
- RUJYJCANMOTJMO-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 RUJYJCANMOTJMO-UHFFFAOYSA-N 0.000 description 2
- WCDNODZFXIBEJD-UHFFFAOYSA-N 5-tert-butyl-4-methyl-1,3-thiazol-2-amine Chemical compound CC=1N=C(N)SC=1C(C)(C)C WCDNODZFXIBEJD-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000005108 alkenylthio group Chemical group 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- DKIXFBUNRHHBCP-UHFFFAOYSA-N n-[1-(cyclopropylmethyl)pyridin-2-ylidene]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)N=C1C=CC=CN1CC1CC1 DKIXFBUNRHHBCP-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000005505 thiomorpholino group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- WYRSGXAIHNMKOL-UHFFFAOYSA-N $l^{1}-sulfanylethane Chemical group CC[S] WYRSGXAIHNMKOL-UHFFFAOYSA-N 0.000 description 1
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical group [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- 125000004719 1,1-dimethylpropylthio group Chemical group CC(CC)(S*)C 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical group C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- ZOQOPXVJANRGJZ-UHFFFAOYSA-N 2-(trifluoromethyl)phenol Chemical compound OC1=CC=CC=C1C(F)(F)F ZOQOPXVJANRGJZ-UHFFFAOYSA-N 0.000 description 1
- ADDZHRRCUWNSCS-UHFFFAOYSA-N 2-Benzofurancarboxaldehyde Chemical group C1=CC=C2OC(C=O)=CC2=C1 ADDZHRRCUWNSCS-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- AXOAWWUSRZCGKS-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1Cl AXOAWWUSRZCGKS-UHFFFAOYSA-N 0.000 description 1
- RIKGRFSGIOOYEK-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzoyl chloride Chemical compound FC1=C(C(Cl)=O)C=CC=C1C(F)(F)F RIKGRFSGIOOYEK-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BDRMZZJHDOSCGO-UHFFFAOYSA-N 3,4-dimethyl-2h-1,3-thiazole Chemical compound CN1CSC=C1C BDRMZZJHDOSCGO-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- XBGXGCOLWCMVOI-UHFFFAOYSA-N 3-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC(C(F)(F)F)=C1 XBGXGCOLWCMVOI-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- FQXQBFUUVCDIRK-UHFFFAOYSA-N 3-trifluoromethylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- LQSBRIMYAZRHNL-UHFFFAOYSA-N C1C=CC=C2C1CC(O2)C=O Chemical group C1C=CC=C2C1CC(O2)C=O LQSBRIMYAZRHNL-UHFFFAOYSA-N 0.000 description 1
- GOFDQEJQQUBQBL-UHFFFAOYSA-N CC1=NC=CC1=C2C=CN=C2 Chemical group CC1=NC=CC1=C2C=CN=C2 GOFDQEJQQUBQBL-UHFFFAOYSA-N 0.000 description 1
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IOEZMAIOBNXQBK-UHFFFAOYSA-N [3-(2-aminoethyl)-5-tert-butyl-1-imino-4-methyl-2H-1,3-thiazol-2-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound NCCN1C(S(C(=C1C)C(C)(C)C)=N)C(C1=CC(=CC=C1)C(F)(F)F)=O IOEZMAIOBNXQBK-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- DXTVYXOAQBXYAU-UHFFFAOYSA-N chloro ethyl carbonate Chemical compound CCOC(=O)OCl DXTVYXOAQBXYAU-UHFFFAOYSA-N 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- NWSBNVVOFKKFNV-UHFFFAOYSA-N chloroform;oxolane Chemical group ClC(Cl)Cl.C1CCOC1 NWSBNVVOFKKFNV-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-OUBTZVSYSA-N chloromethane Chemical group Cl[13CH3] NEHMKBQYUWJMIP-OUBTZVSYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical group C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-M diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)([O-])OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006005 fluoroethoxy group Chemical group 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- KAXFGIFRAWGBOU-UHFFFAOYSA-N n-[5-tert-butyl-2-(cyclopropylmethyl)pyrazol-3-yl]-2,2,2-trifluoroacetamide Chemical compound N1=C(C(C)(C)C)C=C(NC(=O)C(F)(F)F)N1CC1CC1 KAXFGIFRAWGBOU-UHFFFAOYSA-N 0.000 description 1
- WCVDFGYSWQKAQI-UHFFFAOYSA-N n-[5-tert-butyl-3-(2-ethoxyethyl)-4-methyl-1,3-thiazol-2-ylidene]-3-(trifluoromethyl)benzamide Chemical compound CCOCCN1C(C)=C(C(C)(C)C)SC1=NC(=O)C1=CC=CC(C(F)(F)F)=C1 WCVDFGYSWQKAQI-UHFFFAOYSA-N 0.000 description 1
- OCZGZWPFOZMXFE-UHFFFAOYSA-N n-[5-tert-butyl-3-(cyclopropylmethyl)-4-methyl-1,3-thiazol-2-ylidene]naphthalene-1-sulfonamide Chemical compound CC1=C(C(C)(C)C)SC(=NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)N1CC1CC1 OCZGZWPFOZMXFE-UHFFFAOYSA-N 0.000 description 1
- 125000004708 n-butylthio group Chemical group C(CCC)S* 0.000 description 1
- 125000006610 n-decyloxy group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004712 n-pentylthio group Chemical group C(CCCC)S* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004706 n-propylthio group Chemical group C(CC)S* 0.000 description 1
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005475 oxolanyl group Chemical group 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000005005 perfluorohexyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000009366 sericulture Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to an imine compound having a cannapinoid receptor agonistic action (agonist action).
- Cannapinoids are substances isolated as a physiologically active component of marijuana in 1960, and have effects such as analgesia, anxiety, sedation, and euphoria. Later, when the receptor was found, an endogenous ligand having a cannapinoid-like physiological activity such as anandamide was discovered.
- a cannapinoid type 1 (CB1) receptor was discovered in 1990 and found to be distributed in the central nervous system such as the brain.
- the cannapinoid type 2 (CB2) receptor was discovered and distributed to tissues and cells of the immune system including blood cells such as spleen, lymph nodes, leukocytes, B cells, T cells, macrophages, and mast cells.
- the agonist has been shown to exhibit immunosuppressive, anti-inflammatory, and analgesic effects.
- Non-patent documents 1 and 2 disclose compounds having a CB1 receptor agonist action and compounds having a CB2 receptor agonist action.
- Non-Patent Documents 3 to 8, Patent Documents 1 to 20, and the like examples of the imine compound having a structure close to that of the compound of the present invention are described in Non-Patent Documents 3 to 8, Patent Documents 1 to 20, and the like. Its uses include, for example, agricultural fungicides, herbicides, platelet aggregation inhibitors, therapeutic agents for various inflammations caused by leukocyte infiltration inhibition, anti-allergy agents 'anti-inflammatory agents' immunomodulators, analgesics, etc. There have been reports on the use of. However, it has been reported that cannapinoid receptor agonistic action using imine compounds as active ingredients.
- Non-Patent Document 1 Exp.Opin.Ther.Patent (2002) 12 (10): 1475-1489
- Non-Patent Document 2 Exp.Opin.Ther.Patent (2004) 14 (10): 1435-1452
- Non-Patent Document 3 European Journal of Medicinal Chmistry (l 994) 29 (1!): 841-854
- Non-Patent Document 4 Journal of Medicinal Chmistry (1966) 9 (l): 151-153
- Non-Patent Document 5 IzVestiya Akademii Nauk SSSR, Seriya Kimicheskaya (1953): 154-162
- Non-Patent Document 6 Farmaco'Edizione Scientifica (l 985) 40 (3): 178-189
- Non-Patent Document 7 Journal of Heterocyclic Chemistry (1983) 20 (5): 1153-1154
- Non-Patent Document 8 Journal of Heterocyclic Chemistry (l 981) 18 (4): 745-750
- Patent Document 1 W09215564
- Patent Document 2 EP432600
- Patent Document 3 DE1036326
- Patent Document 4 ⁇ ⁇ 02001055139
- Patent Document 5 WO2000063207
- Patent Document 6 JP2003292485
- Patent Document 7 WO2002002542
- Patent Document 8 WO2003097605
- Patent Document 9 _ ⁇ 2003192591
- Patent Document 10 WO2000017196
- Patent Document 11 WO9842703
- Patent Document 12 WO2002002542
- Patent Document 13 JP02250874
- Patent Document 14 JP62004277
- Patent Document 15 EP40573
- Patent Document 16 JP63203672
- Patent Document 17 JP08081449
- Patent Document 18 WO9703058
- Patent Document 19 WO9404516
- Patent Document 20 JP02229164
- An object of the present invention is to provide a novel imine compound having a cannapinoid receptor agonistic action.
- the present invention provides a compound of formula (I)
- A represents any ring represented by the following formulas (wherein X represents an oxygen atom or a sulfur atom, X ′ represents CH or a nitrogen atom),
- R 1 is
- a group that forms a cyclic amino group together with the adjacent nitrogen atom is shown.
- R 62 and R 72 each represent a hydrogen atom or a C alkyl group or are adjacent nitrogen atoms
- Halogen atom C cycloalkyl group, C alkoxycarbonyl group, C haloalkyl
- R 62 and R 72 represent a hydrogen atom or a C alkyl group or are adjacent to each other
- n 0 or 1
- Q represents an integer of 2 to 4, and q represents an integer of 1 to 3.
- C alkyl group optionally substituted by a group represented by:
- An arylsulfonyl group optionally substituted by a C alkyl group or a halogen atom;
- Bi-tro group selected aryl group optionally substituted by 1 to 3 groups
- a heterocyclic group optionally substituted by a C alkyl group or a C haloalkyl group
- R 63 and R 73 are a hydrogen atom, a C alkyl group, a C hydro
- a cyclic amino group optionally substituted with an aryl group
- halogen atom which may be a C alkylsulfol group
- Substituted with a halogen atom may represent an arylsulfonyl group
- C alkyl group or halogen atom may be aryl, pyridyl
- Substituted with a “pyridinole group or a chael group” may be a C alkyl group
- C represents an alkylsulfenyl group
- ⁇ represents an integer of:! ⁇ 3.
- ⁇ represents a group represented by
- a and b are each 0 or 1
- W represents one CO—, one CO—CO—, one CO—NH—, one CS—NH— or one SO — ol
- a cannapinoid receptor agonist comprising an imine compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- a 1 represents any ring represented by the following formulas (wherein X represents an oxygen atom or a sulfur atom),
- R 21 and R 31 are identical to R 21 and R 31.
- C represents an alkyl group
- Halogen atom C cycloalkyl group, “C arnolequinol group, C alkoxy group, C halo
- 1-6 1-6 1-6 aryl group or aryloxy group optionally substituted with 1 to 5 groups selected from alkyl group and norogen atom and heterocyclic group power are selected.
- Y 1 represents — (CH 2) p— or —O— (CH 2) q—O
- p represents an integer of 2 to 4
- R 551 and R 561 are each
- C alkyl group optionally substituted by a group represented by:
- Force may be substituted with 1 to 3 selected groups, aryl groups;
- R 634 and R TM are each a hydrogen atom, a C alkyl group, an aryl,
- Substituted with a halogen atom may represent an arylsulfonyl group
- n represents an integer of 1 to 3.
- a and b each represent 0 or 1
- W represents CO or SO. Or a pharmaceutically acceptable salt thereof.
- the present invention provides a cannapinoid receptor agonist comprising as an active ingredient.
- a 1 represents any ring represented by the following formulas (wherein X represents an oxygen atom or a sulfur atom).
- a group that forms a cyclic amino group together with the adjacent nitrogen atom is shown.
- R 21 and R 31 are identical to R 21 and R 31.
- C represents an alkyl group
- Halogen atom C cycloalkyl group, “C alkyl group, C alkoxy group, C halo
- Y 1 represents — (CH 2) p— or —O— (CH 2) q—O
- p represents an integer of 2 to 4
- R 551 and R 561 are each
- C alkyl group optionally substituted by a group represented by: A C haloalkyl group;
- Force may be substituted with 1 to 3 selected groups, aryl groups;
- R 634 and R TM are each a hydrogen atom, a C alkyl group, an aryl,
- Substituted with a halogen atom may represent an arylsulfonyl group
- n represents an integer of 1 to 3.
- a and b each represent 0 or 1
- W represents CO or SO. Or a pharmaceutically acceptable salt thereof.
- Another embodiment of the present invention is a compound of formula (1-2)
- R 11 and R 22 may be substituted with a C alkyl group or a halogen atom together with adjacent carbon atoms.
- R 42 represents
- Halogen atom cyano group, carboxyl group, C alkoxycarbonyl group, C cyclo
- R 62 and R 72 each represent a hydrogen atom or a C alkyl group or are adjacent to each other
- a group which forms a cyclic amino group together with a nitrogen atom or a C alkyl group or C alkenyl group optionally substituted by a group represented by
- C represents an alkyl group
- Halogen atom C cycloalkyl group, C alkoxycarbonyl group, “C alkoxy
- 3-10 2-6 1-6 Si group or aryl group may be substituted with a C alkoxy group or a C alkyl group.
- C alkyl group An optionally substituted C cycloalkoxy group, “C alkyl group, C haloalkyl group,
- R 62 and R 72 are each a hydrogen atom or C
- 1-6 Indicates an alkyl group or a group that forms a cyclic amino group together with the adjacent nitrogen atom.
- 1-6 1-6 2-6 1-6 substituted with a thio group ! may be an aryloxy group
- n 0 or 1
- Force may be substituted with 1 to 3 selected groups, aryl groups;
- a heterocyclic group optionally substituted by a C alkyl group or a C haloalkyl group
- R 63 and R 73 are a hydrogen atom, a C alkyl group, a C hydro
- 1-6 1-6 1-6 represents a benzoyl group or a group that forms a cyclic amino group together with an adjacent nitrogen atom.
- R 64 and R 74 are a hydrogen atom, a C alkyl group, C An alkoxy c alkyl group or a heterocyclic group optionally substituted by a C alkyl group;
- Substituted with a halogen atom may be a C alkylsulfonyl group
- n represents an integer of 1 to 3.
- X represents an oxygen atom or a sulfur atom
- W represents CO or SO. Or a pharmaceutically acceptable salt thereof.
- the present invention provides a cannapinoid receptor agonist comprising as an active ingredient.
- W is CO
- R 12 is
- R 42 is a C alkyl group substituted with a C cycloalkyl group or a C alkoxy group.
- Another embodiment of the present invention is a compound of formula (I 3)
- X 3 represents C (R 13 ), S or O
- R 13 , R 23 and R 33 are each
- Xyl group and halogen atom ”force is substituted with 1 to 5 groups selected !, may! /, Aryl group or aryloxy group, heterocyclic group, C Alkanoyloxy group, aralkyloxy
- C alkyl optionally substituted by 1 to 3 groups selected from C and C alkylthio groups
- n 0 or 1
- Y 3 represents one O—CH—CH ⁇ CH— or one O— (CH 2) q—O—, and q represents 1 to 3)
- An aryl group which may be substituted with 1 to 3 of a nitro group, a rogen atom or a cyan group; a heterocyclic group;
- C represents a haloalkyl group
- m represents an integer of 1 to 3.
- W represents —CO—, —CO—CO—, —CO—NH, mono-CS—NH or SO.
- a cannabinoid receptor agonist comprising a pharmaceutically acceptable salt as an active ingredient.
- Another embodiment of the present invention is a compound of formula (I 3)
- X 3 represents C (R 13 ), S or O
- R 13 , R 23 and R 33 are each
- a C haloalkyl group A C cycloalkyl group; or
- Xyl group and halogen atom ”force is substituted with 1 to 5 groups selected !, may! /, Aryl group or aryloxy group, heterocyclic group, C Alkanoyloxy group, aralkyloxy
- C alkyl optionally substituted by 1 to 3 groups selected from C and C alkylthio groups
- a C alkoxy group A C alkylthio group;
- An aryl group optionally substituted by 1 to 3 halogen atoms or cyan groups;
- R 633 and R 733 are a hydrogen atom, a C alkyl group, a C
- C represents a haloalkyl group
- m represents an integer of 1 to 3.
- W represents —CO—, —CO—CO—, —CO—NH—, 1 CS—NH— or 1 SO—.
- R 4 , R 41 , R 42 or R 43 is a C alkenyl group or “C cycloalkyl”.
- a C alkyl group substituted with a C group or a C alkoxy group is preferred.
- R 5 , R 51 , R 52 or R 53 is a C cycloalkyl group, “C haloa”.
- 1-6 alkyl group, halogen group, halogen atom and aryloxy group which may be substituted with 1-6 alkyl group or halogen atom C may be substituted with 1 to 3 groups selected
- R 55 , R 551 , R 552 or R 553 is a hydrogen atom; a halogen atom; a C alkyl group; a C neuroalkyl.
- R 56 , R 561 , R 562 or R 563 are a hydrogen atom; a halogen atom; a C normal
- R 57 , R 571 , R 572 or R 573 is a hydrogen atom; halogen
- a compound that is an atom; a C alkyl group or a C alkoxy group is preferred.
- R 5 , R 51 , R 52 or R 53 is a group represented by the formula (11), (11-1), (II-2) or (II-3), respectively, and B is A phenol group, R 55 , R 551 , R 552 or R 553 is a halogen atom; C
- R 56 , R 561 , R 562 or R 563 are a hydrogen atom; a halogen atom; a C neuroalkyl group; or C
- R 57 , R 571 , R 572 or R 573 are a hydrogen atom; a norogen atom; C alkyl
- R 53 is a nitrogen atom, C alkyl group, C haloalkyl group, C alkoxy group,
- the imine compound of the present invention also includes prodrugs, hydrates, and solvates thereof.
- C means that it has a subsequent group of ca to y carbon atoms.
- halogen atom is fluorine, chlorine, bromine or iodine.
- C alkyl group means a linear or branched alkyl group having 1 to 6 carbon atoms.
- examples thereof include a propyl group and an n-hexyl group.
- C alkyl group means a linear or branched alkyl group having 1 to 10 carbon atoms.
- C haloalkyl group means that the “C alkyl group” is one or more halogen atoms.
- C alkoxy group is a straight or branched alkoxy having 1 to 6 carbon atoms.
- methoxy group, ethoxy group, 1 propoxy group, isopropoxy group, 1 butoxy group, 1-methyl-1 propoxy group, t-butoxy group, 1 pentyloxy group and the like can be mentioned.
- C alkoxy group is a linear or branched alkoxy having 1 to 10 carbon atoms.
- An "aryl group” is a monocyclic to tetracyclic aromatic carbocyclic group having 6 to 18 carbon atoms. Examples thereof include a phenyl group, a naphthyl group, an anthryl group, a phenanthryl group, a tetraceryl group, and a pyrenyl group. A phenyl group is preferred.
- C cycloalkyl group is a cycloalkyl group having 3 to 10 carbon atoms, for example
- cyclopropyl group cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, adamantyl group and the like can be mentioned.
- the “C alkenyl group” means one or more double bonds at any position of the “alkyl group”.
- Linear or branched alkyl group having 2 to 6 carbon atoms such as beer group, 1 prop group, 2 prop group, 2 butur group, 1, 3 Butagel group, 2 Pentayl group, 3 Penter group, 2 Hexale group and the like can be mentioned.
- C alkynyl group refers to a linear or branched alkyl having 2 to 6 carbon atoms.
- -L group for example, ethul group, 1-propynyl group, 2-propyl group and the like.
- C alkoxy carbonyl group means that the alkoxy group and the carbo group are bonded to each other.
- Hydrochloroxy C alkyl group means the C alkyl group substituted with 1 to 2 hydroxyl groups.
- 1-6 means 1-6, and examples thereof include a hydroxymethyl group, a 2-hydroxyethyl group, and a 4-hydroxybutyl group.
- the “cyclic amino group” is a cyclic amino group having 2 to 6 carbon atoms, and examples thereof include a pyrrolidino group, a piperidino group, a piperazino group, a morpholino group, and a thiomorpholino group.
- a pyrrolidino group a piperidino group, a piperazino group, a morpholino group, and a thiomorpholino group.
- a dioxide form of a sulfur atom is also included in the present invention.
- C haloalkoxy group means that the “C alkoxy group” is one or more halogens
- An alkoxy group substituted with an atom for example, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a 2,2,2-trifluoroethoxy group, a 2,2,2-trichlorooxy group, a pentafluoro group.
- C alkylthio group refers to a linear or branched alkyl having 1 to 6 carbon atoms.
- C haloalkylthio group means that said “C alkylthio group” is one or more halo
- An alkylthio group substituted with a gen atom such as a fluoromethylthio group, a difluoromethylthio group, a trifluoromethylthio group, a 2,2,2-trifluoroethylthio group, a 2,2,2 trichloroethyl group, Examples thereof include a ruthio group, a pentafluoroethylthio group, a 4 fluorobutylthio group, a 4 chlorobutylthio group, a 4-bromobutylthio group, and a perfluorohexylthio group.
- arylthio group examples include a phenolthio group and a naphthylthio group.
- the "C alkyl thio group” is a linear or branched alkyl having 26 carbon atoms.
- vinylthio group 1-propenylthio group, 2-propenylthio group, 2 butenylthio group, 1,3 butadiene gelthio group, 2 pentenylthio group, 3 penterthio group, 2 —Hexalthio group and the like can be mentioned.
- C alkanoyl group refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms.
- a neutral group for example, a formyl group, a acetyl group, a propionyl group, an isopropionyl group, a petityl group, a bivaloyl group, and the like.
- the "C alkanoyloxy group” is a group in which the C alkanoyl group and the oxy group are bonded.
- C alkanoyloxy C alkyl group means the above C alkanoyloxy group and C
- 1-6 1-6 1-6 1-6 This means a group to which an alkyl group is bonded, and examples thereof include an acetyloxyxetyl group, a propio-oxymethyl group, and a bivalyloxymethyl group. ;
- C haloalkanoyl group means that “c alkanoyl group” is substituted with a halogen atom.
- alkanoyl group for example, a fluoroacetyl group, a trifluoroacetyl group, a 2,2,2 trifluoropropiol group, a 2,2,2 trichloropropiol group, a 4 fluorobutylyl group, a 4 chlorobutyryl group, 4-bromobutyryl group and the like can be mentioned.
- C alkoxy alkoxy group means a group in which two C alkoxy groups are bonded.
- Examples thereof include a methoxymethoxy group, a methoxypropoxy group, an ethoxypropoxy group, and a heptyloxyethoxy group.
- C alkoxy alkoxy group means a C alkoxy group bonded to a C alkyl group.
- Examples thereof include methoxymethyl group, methoxypropyl group, ethoxypropyl group, heptyloxetyl group and the like.
- aryloxy group is a group in which the “aryl group” is substituted via an oxygen atom, and examples thereof include a phenoxy group and a naphthoxy group.
- aralkyl group means a group in which an aryl group and an alkyl group are bonded, and examples thereof include a benzyl group, a phenethyl group, and a naphthylmethyl group.
- Alkyloxy group means a group in which an aralkyl group and an oxy group are bonded, and examples thereof include a benzyloxy group, a phenethyloxy group, and a naphthylmethoxy group.
- the heterocyclic group is preferably a heterocyclic ring having 5 to 10 atoms in the ring system.
- saturated heterocyclic group examples include aziridinyl group, azetidinyl group, pyrrolidinyl group, imidazolidyl group, virazolidinyl group, oxolanyl group, thiolanyl group, piperidinyl group, piperazil group, morpholinyl group and the like.
- Examples of the aromatic heterocyclic group include a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, a quinolyl group, an isoquinolyl group, and a chael group (for example, a 2-chell group and a 3-thienyl group).
- Pyrrolyl group for example, 1 pyrrolyl group, 2 pyrrolyl group, 3 pyrrolyl group
- thiazolyl group for example, 2 thiazolyl group, 4 thiazolyl group, 5 thiazolyl group
- isothiazolyl group for example, 3-isothiazolyl group, 4 Isothiazolyl group, 5-isothiazolyl group
- pyrazolyl group eg 1 pyrazolyl group, 3 pyrazolyl group, 4 pyrazolyl group
- imidazolyl group eg ⁇ imidazolyl group, 2 imidazolyl group, 3 imidazolyl group
- a tolyl group for example, 2 furyl group, 3 furyl group
- an oxazolyl group for example, 2-year-old xazolyl group, 4-oxazolyl group, 5-oxazolyl group
- an isoxazolyl group for example, 3-isoxazolyl group,
- Examples of the condensed cyclic heterocyclic group having a monocyclic ring in which the aromatic heterocyclic group is partially saturated include, for example, a tetrahydrobenzofural group, a tetrahydrobenzozo group, a tetrahydrobenzopyrrolyl group, and a 2,3 dihydro group.
- the heterocyclic group of the B ring is preferably a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyradyl group, a quinolyl group or an isoquinolyl group.
- C alkylsulfuryl group means that the above “C alkyl group” is substituted via SO
- Examples thereof include a methylsulfur group, ethylsulfur group, n-propylsulfuryl group, n -butylsulfuryl group, t-butylsulfuryl group, n-pentylsulfuryl group and the like.
- 1-6 1-6 alkyl group or the above-mentioned c haloalkyl group "is a group substituted through a sulfo group.
- methylsulfol group ethylsulfol group, n-propylsulfol group, n-butylsulfol group, t-butylsulfol group, npentylsulfol group, fluoromethylsulfol group, difluoro Methylsulfol group, trifluoromethylsulfol group, 2,2,2-trifluoroethylsulfol group, 2,2,2-trichloroethylsulfol group, pentafluoroethylsulfol group -L group, 4 fluorobutyl sulfol group, 4 chlorobutyl sulfol group, 4 bromobutyl sulfol group and the like.
- Arylaryl group refers to a sulfole group in which the aryl group may be substituted with a halogen atom.
- Prodrug means a compound that is hydrolyzed in vivo to regenerate an imine compound having a cannapinoid receptor agonistic action.
- “Pharmaceutically acceptable salts” are acid addition salts and base addition salts.
- acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, etc. Chenate, oxalate, malate, tartrate, fumarate, maleate, methanesulfonate, ethanesulfonate, benzenesulfonate, paratoluenesulfonate, benzoate, asparagine And organic acid salts such as acid salts and glutamates.
- Examples of the base addition salt include inorganic base salts such as sodium salt, calcium salt, magnesium salt, calcium salt, aluminum salt, ethanolamine salt, lysine salt, orthotin salt, medalmine salt, trishydroxymethylaminomethane.
- examples thereof include organic base salts such as salts and ammonium salts.
- the compound of the present invention can be produced by the following steps (1) to (4).
- the compound (la) of the present invention can be produced, for example, from the amine compound (V) by the method shown by the following reaction formula.
- Q 1 represents a hydroxyl group or a halogen atom such as a chlorine atom or a bromine atom
- Q 2 represents a chlorine atom, a bromine atom, an iodine atom, a methanesulfoloxy group, trifluoro
- leaving groups such as chloromethane sulfo-loxy group, para-toluene sulfo-loxy group
- W 1 is —CO—, —CO—CO— or —SO— Indicates.
- Amidy compound (VII) can be produced by carrying out amidy reaction using amine compound (V) and compound (VI).
- the reaction is preferably carried out the reaction in the presence of a base.
- Bases used include alkali metal hydroxides (lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonates (lithium carbonate, sodium carbonate, potassium carbonate, etc.), alkali metal bicarbonates ( Sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), organic bases (triethylamine, diisopropylethylamine, tri-n-butylamine, 1,5-diazabicyclo [4.3.0] -5 nonene, 1,8 diazabicyclo [5.4. 0] -7 undecene, pyridine, ⁇ , ⁇ dimethylaminopyridine, etc.).
- the reaction temperature is preferably a temperature up to the boiling point of the solvent or reagent to be used under cooling force, particularly preferably 20 ° C to room temperature.
- the reaction can be carried out without solvent or in a solvent.
- Solvents used include dioxane, tetrahydrofuran, jetyl ether, petroleum ether, n- xane, cyclohexane, benzene, toluene, xylene, black benzene, pyridine, acetonitrile, ethyl acetate, ethylmethyl ketone, ⁇ , ⁇ ⁇ ⁇ ⁇ Dimethylformamide, dimethyl sulfoxide, dichloromethane, black mouth form, carbon tetrachloride, water and the like.
- the types of solvents and reagents to be used and the amounts used thereof are preferably selected as appropriate depending on the substrate and reaction conditions used in the reaction.
- Q 1 of the compound (VI) is a hydroxyl group
- a condensing agent examples include acid halogenating agents such as chlorothionyl and oxalyl chloride.
- Chlorodiethyl carbonate such as chloroethyl carbonate, dicyclohexylcarbodiimide, carbodiimide compounds such as 1-ethyl 3 1- (3-dimethylamino) propylcarbodiimide, sulfonyl chloride compounds such as methanesulfuryl chloride, diphenyl phosphate, Examples thereof include phosphorus compounds such as diphenylphosphyl chloride, triphenylphosphine-jetylazodicarboxylate, and ⁇ , ⁇ ′-carbodiimidazole.
- This reaction can be carried out without solvent or in a solvent.
- a solvent to be used methanol , Ethanol, n - propanol, isopropanol, n- butanol, t chromatography butanol, Jiokisan, tetrahydrofuran, Jefferies Chino Les ether Honoré, petroleum Etenore, n-hexane, cyclohexane, benzene, toluene, xylene, black hole benzene, pyridine, acetic acid Ethyl, ⁇ , ⁇ -dimethylformamide, dimethyl sulfoxide, dichloromethane, black mouth form, carbon tetrachloride, water and the like.
- bases preferably used in the presence of a base include alkali metal hydroxides (lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonates (lithium carbonate, carbonate carbonate). Sodium, potassium carbonate, etc.), alkali metal hydrogen carbonates (sodium hydrogen carbonate, potassium bicarbonate, etc.), organic bases (triethylamine, diisopropylethylamine, tri-n-butylamine, 1,5 diazabicyclo [4.3. 0] -5 nonene, 1,8 diazabic mouth [5.4.0] -7 undecene, pyridine, ⁇ , ⁇ -dimethylaminopyridine, etc.).
- the reaction temperature is preferably a temperature up to the boiling point of the solvent or reagent used in the cooling force.
- this reaction can be carried out without solvent or in a solvent.
- the solvent used methanol, ethanol, eta - propanol, isopropanol, .eta. butanol, t Buta Nonore, Jiokisan, tetrahydrofuran, Jefferies Chino Les ether Honoré, petroleum Etenore, n key Sun, cyclohexane, benzene, toluene, Xylene, black benzene, pyridine, acetate-tolyl, ethyl acetate, ethyl methyl ketone, ⁇ , ⁇ ⁇ ⁇ ⁇ dimethylformamide, dimethyl sulfoxide, dichloromethane, black chloroform, carbon tetrachloride, water and the like.
- Step 2 Production of compound (la) of the present invention
- the compound (la) of the present invention can be produced by reacting the amido compound (VII) with the compound (VIII).
- bases preferably used in the presence of a base include alkali metal hydroxides (lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonates (lithium carbonate, carbonate carbonate).
- alkali metal hydrogen carbonates sodium hydrogen carbonate, potassium hydrogen carbonate, etc.
- alkali metal hydrides sodium hydride, potassium hydride, etc.
- alkali metals metal sodium, metal potassium, etc.
- Organic bases triethylamine, diisopropylethylamine, tri-n-butylamine, 1,5 diazabicyclo [4.3.0] — 5 —nonene, 1,8 diazabicyclo [5.4.0] — 7 undecene, pyridine, ⁇ , ⁇ ⁇ ⁇ Dimethylaminopyridine, etc.
- alkali metal amides sodium amide, etc.
- alkali metal alkoxides sodium methoxide, sodium Umuetokishido, t-butoxy potassium, etc.
- organometallic compounds organometallic compounds
- the reaction temperature is preferably a temperature up to the boiling point of the solvent or reagent used in the cooling force.
- this reaction can be performed without a solvent or in a solvent.
- the solvent used methanol, ethanol, n - propanol, isopropanol, n- butanol, t Buta Nonore, hexane Jiokisan, tetrahydrofuran, Jefferies Chino Les ether Honoré, petroleum Etenore, n key Sun, cyclohexane, benzene, toluene, Xylene, black benzene, pyridine, ethyl acetate, ⁇ ⁇ , ⁇ dimethylformamide, dimethyl sulfoxide, dichloromethane, chloroform, carbon tetrachloride and the like.
- the types of solvents and reagents to be used and the amounts used thereof are preferably selected as appropriate depending on the substrate and reaction conditions used in the reaction.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007122351/04A RU2007122351A (ru) | 2004-11-15 | 2005-10-31 | Иминовое соединение |
AU2005303223A AU2005303223A1 (en) | 2004-11-15 | 2005-10-31 | Imine compound |
JP2006544838A JPWO2006051704A1 (ja) | 2004-11-15 | 2005-10-31 | イミン化合物 |
EP05800461A EP1820504A1 (en) | 2004-11-15 | 2005-10-31 | Imine compound |
US11/667,728 US20080312435A1 (en) | 2004-11-15 | 2005-10-31 | Imine Compound |
CA002587667A CA2587667A1 (en) | 2004-11-15 | 2005-10-31 | Imine compound |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004330080 | 2004-11-15 | ||
JP2004330079 | 2004-11-15 | ||
JP2004-330080 | 2004-11-15 | ||
JP2004-330079 | 2004-11-15 | ||
JP2005-162163 | 2005-06-02 | ||
JP2005162163 | 2005-06-02 | ||
JP2005-209774 | 2005-07-20 | ||
JP2005209774 | 2005-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006051704A1 true WO2006051704A1 (ja) | 2006-05-18 |
Family
ID=36336386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/019977 WO2006051704A1 (ja) | 2004-11-15 | 2005-10-31 | イミン化合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20080312435A1 (ja) |
EP (1) | EP1820504A1 (ja) |
JP (1) | JPWO2006051704A1 (ja) |
AU (1) | AU2005303223A1 (ja) |
CA (1) | CA2587667A1 (ja) |
RU (1) | RU2007122351A (ja) |
WO (1) | WO2006051704A1 (ja) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006114093A1 (en) * | 2005-04-25 | 2006-11-02 | H. Lundbeck A/S | Pro-drugs of n-thiazol-2yl-benzamide derivatives |
WO2007140385A2 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
WO2007140439A2 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
WO2008029825A1 (fr) | 2006-09-05 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Dérivé d'imidazole |
WO2008032764A1 (fr) | 2006-09-13 | 2008-03-20 | Kyowa Hakko Kirin Co., Ltd. | Dérivé hétérocyclique fusionné |
WO2008121558A1 (en) * | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
WO2008130953A2 (en) * | 2007-04-17 | 2008-10-30 | Abbott Laboratories | 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands |
WO2008144360A1 (en) | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
WO2010004761A1 (ja) * | 2008-07-10 | 2010-01-14 | 一般社団法人ファルマIp | キノリンカルボキサミド誘導体を有効成分とするstat3阻害剤 |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
US20100249087A1 (en) * | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2011500579A (ja) * | 2007-10-12 | 2011-01-06 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規化合物 |
US7868038B2 (en) | 2006-08-31 | 2011-01-11 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2011504186A (ja) * | 2007-11-21 | 2011-02-03 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物およびその使用 |
US7910613B2 (en) | 2004-09-22 | 2011-03-22 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
JP2011513495A (ja) * | 2008-03-11 | 2011-04-28 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US20110144165A1 (en) * | 2009-12-16 | 2011-06-16 | Abbott Laboratories | Prodrug compounds useful as cannabinoid ligands |
US7985768B2 (en) | 2006-08-31 | 2011-07-26 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8044071B2 (en) | 2007-10-18 | 2011-10-25 | Abbott Laboratories | Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist |
US8173687B2 (en) | 2008-08-15 | 2012-05-08 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8188135B2 (en) | 2008-09-16 | 2012-05-29 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2013031671A1 (ja) * | 2011-08-26 | 2013-03-07 | Meiji Seikaファルマ株式会社 | 有害生物防除剤の製造法 |
US8501794B2 (en) | 2007-04-17 | 2013-08-06 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
EP2634174A2 (en) | 2012-02-29 | 2013-09-04 | Meiji Seika Pharma Co., Ltd. | Nitrogen-containing hetercyclic derivate having 2-imino group and pest control agent including the same |
US8586596B2 (en) | 2010-06-15 | 2013-11-19 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8895592B2 (en) | 2008-12-16 | 2014-11-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US20150274714A1 (en) * | 2012-09-28 | 2015-10-01 | Xavier University Of Louisiana | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
US20160227777A1 (en) * | 2013-09-19 | 2016-08-11 | Basf Se | N-Acylimino Heterocyclic Compounds |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
WO2024024961A1 (ja) * | 2022-07-29 | 2024-02-01 | 住友ファーマ株式会社 | 2(1h)-ピリジンイミン誘導体 |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2086970B1 (en) * | 2006-08-24 | 2014-02-26 | Novartis AG | 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
US8236835B2 (en) * | 2006-09-22 | 2012-08-07 | Novartis Ag | Heterocyclic inhibitors of stearoyl-CoA desaturase |
WO2008063781A2 (en) * | 2006-10-12 | 2008-05-29 | Abbott Laboratories | Chemical compounds as cannabinoid receptor ligands |
KR20090091337A (ko) * | 2006-12-20 | 2009-08-27 | 노파르티스 아게 | Scd 억제제로서의 2-치환 5-원 헤테로사이클 |
US8158663B2 (en) | 2006-12-22 | 2012-04-17 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
EP2411371B1 (en) | 2009-03-27 | 2015-05-20 | AbbVie Inc. | Compounds as cannabinoid receptor ligands |
US8492371B2 (en) * | 2009-03-27 | 2013-07-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
BR112016026941A2 (pt) * | 2014-05-19 | 2018-07-10 | Syngenta Participations Ag | derivados de amida ativos do ponto de vista inseticida com grupos fenila ou piridina substituídos com enxofre. |
TW201613866A (en) * | 2014-07-07 | 2016-04-16 | Bayer Cropscience Ag | Process for preparing fluorinated iminopyridine compounds |
US10494366B2 (en) | 2014-12-01 | 2019-12-03 | Syngenta Participations Ag | Pesticidally active amide heterocyclic derivatives with sulphur containing substituents |
WO2016115013A1 (en) * | 2015-01-12 | 2016-07-21 | Janssen Pharmaceutica Nv | Cinnoline derivatives useful as cb-1 receptor inverse agonists |
EP3118199A1 (de) * | 2015-07-13 | 2017-01-18 | Bayer CropScience AG | Herbizid wirksame n-(tetrazol-5-yl)-, n-(triazol-5-yl)- und n-(1,3,4-oxadiazol-2-yl)arylcarboxamid-derivate |
CR20220661A (es) * | 2016-06-23 | 2023-02-21 | Hoffmann La Roche | NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615) |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3149990A (en) * | 1962-01-19 | 1964-09-22 | Minnesota Mining & Mfg | Heat-sensitive copy-sheet |
US3253913A (en) * | 1960-10-13 | 1966-05-31 | Eastman Kodak Co | Process for color electrophotography |
US3455932A (en) * | 1967-08-23 | 1969-07-15 | Smithkline Corp | 2-arylsulfonyliminoquinoline compounds |
US3655895A (en) * | 1969-07-07 | 1972-04-11 | Ciba Geigy Corp | Methods of treatment using 2-acylimino-1 3-diazacycloalkanes |
JPS55162765A (en) * | 1979-05-29 | 1980-12-18 | Ciba Geigy Ag | Guanidine* its manufacture* drug blend containing same and its use |
JPS5731665A (en) * | 1980-05-19 | 1982-02-20 | Roussel Uclaf | 2-position substituted 4-hydroxy-3-quinoline carboxylic acid novel derivative, manufacture, use as drug and composition and novel intermediate containing same |
JPS57171986A (en) * | 1981-04-14 | 1982-10-22 | Taiho Yakuhin Kogyo Kk | Heterocylic ring compound containing sulfur |
JPS5880634A (ja) * | 1981-11-09 | 1983-05-14 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真乳剤 |
JPS60233067A (ja) * | 1984-05-07 | 1985-11-19 | Mitsui Toatsu Chem Inc | 2−イミノ−1,3,4−チアジアゾリン誘導体、製造法及びその化合物からなる農園芸用殺菌剤 |
JPH01149781A (ja) * | 1987-10-26 | 1989-06-12 | Pfizer Inc | ベンゾチアジンジオキシド誘導体 |
JPH03190859A (ja) * | 1989-12-14 | 1991-08-20 | Bayer Ag | 2―イミノピリジン誘導体、その製法及び該誘導体からなる除草剤 |
JP2001026541A (ja) * | 1993-12-02 | 2001-01-30 | Sanofi-Synthelabo | 置換されたn−ピペリジノ−ピラゾール−3−カルボキサミド |
JP2001515470A (ja) * | 1997-02-21 | 2001-09-18 | バイエル・アクチエンゲゼルシヤフト | アリールスルホンアミド及びそれらの類似体並びに神経変性疾患の治療におけるそれらの使用 |
JP2003192591A (ja) * | 2001-12-27 | 2003-07-09 | Sumitomo Pharmaceut Co Ltd | 5員環化合物からなる医薬 |
WO2003070277A1 (fr) * | 2002-02-19 | 2003-08-28 | Shionogi & Co., Ltd. | Antiprurigineux |
JP2003292485A (ja) * | 2002-04-01 | 2003-10-15 | Yamanouchi Pharmaceut Co Ltd | スルホンアミド誘導体 |
WO2003097605A1 (en) * | 2002-05-16 | 2003-11-27 | Bayer Cropscience Gmbh | Pesticidal pyridinecarboxamide derivatives |
WO2004029204A2 (en) * | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
WO2005000825A1 (ja) * | 2003-06-27 | 2005-01-06 | Dainippon Sumitomo Pharma Co., Ltd. | チアゾールイミン類およびオキサゾールイミン類 |
WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342764A (en) * | 1979-05-29 | 1982-08-03 | Ciba-Geigy Corporation | Guanidine compounds, pharmaceutical compositions and use |
EP0973771A1 (de) * | 1997-03-24 | 2000-01-26 | Basf Aktiengesellschaft | Thiazolimin-derivate |
DE19843766A1 (de) * | 1998-09-24 | 2000-03-30 | Bayer Ag | Substituierte Thiazol(in)ylidenaminosulfonylamino(thio)carbonyl-triazolinone |
PT1300401E (pt) * | 2000-06-30 | 2010-01-25 | Dainippon Sumitomo Pharma Co | Derivados de tiazole para utilização como anti-inflamatórios |
-
2005
- 2005-10-31 US US11/667,728 patent/US20080312435A1/en not_active Abandoned
- 2005-10-31 AU AU2005303223A patent/AU2005303223A1/en not_active Abandoned
- 2005-10-31 CA CA002587667A patent/CA2587667A1/en not_active Abandoned
- 2005-10-31 JP JP2006544838A patent/JPWO2006051704A1/ja active Pending
- 2005-10-31 EP EP05800461A patent/EP1820504A1/en not_active Withdrawn
- 2005-10-31 RU RU2007122351/04A patent/RU2007122351A/ru not_active Application Discontinuation
- 2005-10-31 WO PCT/JP2005/019977 patent/WO2006051704A1/ja active Application Filing
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3253913A (en) * | 1960-10-13 | 1966-05-31 | Eastman Kodak Co | Process for color electrophotography |
US3149990A (en) * | 1962-01-19 | 1964-09-22 | Minnesota Mining & Mfg | Heat-sensitive copy-sheet |
US3455932A (en) * | 1967-08-23 | 1969-07-15 | Smithkline Corp | 2-arylsulfonyliminoquinoline compounds |
US3655895A (en) * | 1969-07-07 | 1972-04-11 | Ciba Geigy Corp | Methods of treatment using 2-acylimino-1 3-diazacycloalkanes |
JPS55162765A (en) * | 1979-05-29 | 1980-12-18 | Ciba Geigy Ag | Guanidine* its manufacture* drug blend containing same and its use |
JPS5731665A (en) * | 1980-05-19 | 1982-02-20 | Roussel Uclaf | 2-position substituted 4-hydroxy-3-quinoline carboxylic acid novel derivative, manufacture, use as drug and composition and novel intermediate containing same |
JPS57171986A (en) * | 1981-04-14 | 1982-10-22 | Taiho Yakuhin Kogyo Kk | Heterocylic ring compound containing sulfur |
JPS5880634A (ja) * | 1981-11-09 | 1983-05-14 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真乳剤 |
JPS60233067A (ja) * | 1984-05-07 | 1985-11-19 | Mitsui Toatsu Chem Inc | 2−イミノ−1,3,4−チアジアゾリン誘導体、製造法及びその化合物からなる農園芸用殺菌剤 |
JPH01149781A (ja) * | 1987-10-26 | 1989-06-12 | Pfizer Inc | ベンゾチアジンジオキシド誘導体 |
JPH03190859A (ja) * | 1989-12-14 | 1991-08-20 | Bayer Ag | 2―イミノピリジン誘導体、その製法及び該誘導体からなる除草剤 |
JP2001026541A (ja) * | 1993-12-02 | 2001-01-30 | Sanofi-Synthelabo | 置換されたn−ピペリジノ−ピラゾール−3−カルボキサミド |
JP2001515470A (ja) * | 1997-02-21 | 2001-09-18 | バイエル・アクチエンゲゼルシヤフト | アリールスルホンアミド及びそれらの類似体並びに神経変性疾患の治療におけるそれらの使用 |
JP2003192591A (ja) * | 2001-12-27 | 2003-07-09 | Sumitomo Pharmaceut Co Ltd | 5員環化合物からなる医薬 |
WO2003070277A1 (fr) * | 2002-02-19 | 2003-08-28 | Shionogi & Co., Ltd. | Antiprurigineux |
JP2003292485A (ja) * | 2002-04-01 | 2003-10-15 | Yamanouchi Pharmaceut Co Ltd | スルホンアミド誘導体 |
WO2003097605A1 (en) * | 2002-05-16 | 2003-11-27 | Bayer Cropscience Gmbh | Pesticidal pyridinecarboxamide derivatives |
WO2004029204A2 (en) * | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
WO2005000825A1 (ja) * | 2003-06-27 | 2005-01-06 | Dainippon Sumitomo Pharma Co., Ltd. | チアゾールイミン類およびオキサゾールイミン類 |
WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
Non-Patent Citations (81)
Title |
---|
ARCHIV DER PHARMAZIE, vol. 313, no. 10, 1980, pages 867 - 878 * |
ARZNEIMITTEL-FORSCHUNG, vol. 14, 1964, pages 348 - 356 * |
ARZNEIMITTEL-FORSCHUNG, vol. 14, no. 12, 1964, pages 1294 - 1301 * |
BAILEY A.S. ET AL: "Reactions of dihydroquinolines and dihydroisoquinolines with arenesulfonyl azides", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY, no. 5, 1975, pages 420 - 424, XP002997202 * |
BAILEY A.S. ET AL: "Reactions of p-toluenesulfonyl azide with derivatives of cyclohept- and cyclooctindole", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY, no. 7, 1974, pages 763 - 770, XP002997203 * |
BER., vol. 55B, 1922, pages 998 - 1002 * |
BOSIN T.R. ET AL: "Routes to functionalized guanidines. The synthesis of guanidino diesters", JOURNAL OF ORGANIC CHEMISTRY, vol. 38, no. 8, 1973, pages 1591 - 1600, XP002997204 * |
CHEMISCHE BERICHTE, vol. 100, no. 5, 1967, pages 1655 - 1660 * |
CHEMISCHE BERICHTE, vol. 87, 1954, pages 68 - 78 * |
COLETTE N. ET AL: "New Quaternary Ammonium Oxicam Derivatives Targeted toward Cartilage: Synthesis, Pharmacokinetic Studies, and Antiinflammatory Potency", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 25, 1999, pages 5235 - 5240, XP002165071 * |
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 64, no. 2, 1999, pages 299 - 312 * |
DATABASE CAPLUS [online] ALEMAGNA A. ET AL: "N-Alkyl thiadiazolium salts: reactions with bases", XP002997220, accession no. STN Database accession no. 1980:408093 * |
DATABASE CAPLUS [online] ANDREANI A. ET AL: "Ring-opened analgs of indomethacin affecting human neutrophil functions", XP002996389, accession no. STN Database accession no. 1999:218957 * |
DATABASE CAPLUS [online] BAILEY A.S. ET AL: "Reactions of aresulfonyl azides with some di- and trisubstituted indoles", XP002997205, accession no. STN Database accession no. 1972:14245 * |
DATABASE CAPLUS [online] BOBERG F. ET AL: "Reaction of thioxo compounds with N-chloramidines. VI. Reaction of thioquinolone, dihydrothiazolethione and dihydroisothiazole thione with sodium N-chlorobenzenesulfonamides", XP002945581, accession no. STN Database accession no. 1996:420288 * |
DATABASE CAPLUS [online] BOBERG F. ET AL: "Reaction of thioxoheterocycles with N-chloroamides. II. N-substituted 2- or 4-thiopyridone and sodium N-chlorobenzenesulfonamide", XP002996397, accession no. STN Database accession no. 1990:216635 * |
DATABASE CAPLUS [online] CHICHIBABIN A.E. ET AL: "Benzoylation products of alpha-aminopyridine", XP002997216, accession no. STN Database accession no. 1922:21367 * |
DATABASE CAPLUS [online] DAIDONE G. ET AL: "Synthesis and pharmacological activity of new salicylic acid derivatives", XP002996391, accession no. STN Database accession no. 1985:416394 * |
DATABASE CAPLUS [online] DE BENEDETTI P.G. ET AL: "Structure-activity relationships: electronic features of sulfanilamides and p-aminobenzoate in relation to their competitive affinities in bacterial growth", XP002996398, accession no. STN Database accession no. 1980:88490 * |
DATABASE CAPLUS [online] GEHLEN H. ET AL: "2-Amino-1,3,4-oxadiazoles. 34. Reaction of 3,5-disubstituted 2-imino-1,3,4-oxadiazolines with mustard oils", XP002997224, accession no. STN Database accession no. 1970:121461 * |
DATABASE CAPLUS [online] GEHLEN H. ET AL: "2-Amino-1,3,4-oxadiazoles. XXIII. Preparation and reactions of 2-amino-1,3,4-oxadiazoles from aromatic dihydroxy-, di- and trialkoxycarboxylic acid hydrazides and the effect of phenyl isocyanate on 2-imino-1,3,4-oxadiazolines", XP002997225, accession no. STN Database accession no. 1968:496593 * |
DATABASE CAPLUS [online] GOERDELER J. ET AL: "1,2,4-Thiadiazoles. II. N-Methyl derivatives of the aminothiadiazoles and iminothiadiazolines", XP002997211, accession no. STN Database accession no. 1955:32380 * |
DATABASE CAPLUS [online] KANAOKA M.: "Synthesis of related compounds of thiosemicarbazides. VI. Alkylation of 2-(p-toluenesulfonamido)-1,3,4-thiadiazole", XP002997209, accession no. STN Database accession no. 1962:38480 * |
DATABASE CAPLUS [online] KRESZE G. ET AL: "Reactions with N-sulfinyl compounds. VII. Reactions with N-acyl thioureas, dithiocarboxylic acid esters, and trithiones", XP002997226, accession no. STN Database accession no. 1967:421872 * |
DATABASE CAPLUS [online] MASTRYUKOVA T.A. ET AL: "Application of the Hammett equation to the theory of tautomeric equilibrium. II.Tautomerism of alpha-arylsulfoaminopyridines", XP002997208, accession no. STN Database accession no. 1963:80949 * |
DATABASE CAPLUS [online] MELEGARI M. ET AL: "Preparation and spectroscopic behavior of acetylderivatives of sulphonamides", XP002997201, accession no. STN Database accession no. 1976:180162 * |
DATABASE CAPLUS [online] NEITZEL M. ET AL: "Reaction of cyanates with N- and N'-substituted carboxylic hydrazides", XP002997218, accession no. STN Database accession no. 1981:65569 * |
DATABASE CAPLUS [online] PAPADOPOULOU-DAIFOTIS Z. ET AL: "Synthesis and pharmacological activity of some 2-imino-3-alkylthiazoline derivatives", XP002996392, accession no. STN Database accession no. 1981:30616 * |
DATABASE CAPLUS [online] PAPADOPOULOU-DAIFOTIS Z. ET AL: "Synthesis and pharmacological activity of some2-imino-3-alkyl thiazoline derivatives", XP002996393, accession no. STN Database accession no. 1979:557647 * |
DATABASE CAPLUS [online] PELLIZZARI G.: "Action of cyanogen halides on phenylhydrazine. X. Derivatives of diazole", XP002997230, accession no. STN Database accession no. 1927:7474 * |
DATABASE CAPLUS [online] PETKO K.I. ET AL: "Difluoromethylation of Sulfonamides", XP002996396, accession no. STN Database accession no. 2002:817633 * |
DATABASE CAPLUS [online] POLYAKOVA I.M. ET AL: "Preparation of sulfidine and certain new derivatives of streptocide", XP002997215, accession no. STN Database accession no. 1941:13409 * |
DATABASE CAPLUS [online] RACKHAM D.M. ET AL: "Carbon-13 NMR spectra of 1,3,4-thiadiazole/thiadiazoline isomeric pairs", XP002997217, accession no. STN Database accession no. 1981:441647 * |
DATABASE CAPLUS [online] RAJAGOPALAN S.: "Bacterial chemotherapy. III. Synthesis of possible lipophilic chemotherapeuticals of the sulfanilamide group", XP002997213, accession no. STN Database accession no. 1944:8285 * |
DATABASE CAPLUS [online] RASTELLI A. ET AL: "Experimental investigations on the mechanisms of intramolecular interactions in sulfanilamides", XP002996399, accession no. STN Database accession no. 1977:483969 * |
DATABASE CAPLUS [online] SCHOLTAN W.: "The binding of sulfonamides with proteins", XP002997206, accession no. STN Database accession no. 1964:435373 * |
DATABASE CAPLUS [online] SCHUBERT W.M. ET AL: "The acidity dependence of the carbon protonation of phloroglucinol and its methyl ethers", XP002997207, accession no. STN Database accession no. 1963:80950 * |
DATABASE CAPLUS [online] SEYDEL J. ET AL: "Sulfanilamidopyrazole derivatives", XP002997227, accession no. STN Database accession no. 1965:82505 * |
DATABASE CAPLUS [online] SEYDEL J.: "5-Sulfanilamido-1-phenylpyrazole", XP002997228, accession no. STN Database accession no. 1964:23364 * |
DATABASE CAPLUS [online] SHEINKER Y.N. ET AL: "Tautomerism of derivatives of heterocyclic compounds. X. Tautomerism of acylated heterocyclic amines", XP002997210, accession no. STN Database accession no. 1960:62765 * |
DATABASE CAPLUS [online] SHEINKER Y.N. ET AL: "Tautomerism of some derivatives of heterocyclic compounds. IV. Spectra and the structure of benzene sulfonamides and the thiozole and thiodiazole sulfonamides", XP002997229, accession no. STN Database accession no. 1958:33499 * |
DATABASE CAPLUS [online] SHEPHERD R.G. ET AL: "Hydrolysis and aminolysis of certain methoxypyrimidines", XP002997212, accession no. STN Database accession no. 1947:27500 * |
DATABASE CAPLUS [online] SHEPHERD R.G. ET AL: "Properties of the nitrogen-carbon-nitrogen system in N1-heterocyclic sulfanilamides", XP002997214, accession no. STN Database accession no. 1943:3566 * |
DATABASE CAPLUS [online] SONDHI S.M. ET AL: "Synthesis and anti-inflammatory activity evaluation of some acridinylaminoantipyrine, acridinylaminoanthraquinone, acridinothiourea and thiazolinothiourea derivatives", XP002996388, accession no. STN Database accession no. 2000:530801 * |
DATABASE CAPLUS [online] VASIL'EVA V.F. ET AL: "Synthesis and properties of 2-imino-3-benzyl-5-phenyl-1,3,4-oxadiazoline", XP002996394, accession no. STN Database accession no. 1970:121444 * |
DATABASE CAPLUS [online] WERBER G. ET AL: "Nucleophilic behavior of some 1,3,4-oxadiazoles in benzoylation, nitrosation, acetylation, and methylation reactions", XP002997223, accession no. STN Database accession no. 1972:99563 * |
DATABASE CAPLUS [online] WERBER G. ET AL: "Reactivity of 2-amino-1,3,4-thiadiazoles. Nucleophilic behavior of some 2-amino-1,3,4-thiadiazoles: model compounds", XP002997222, accession no. STN Database accession no. 1978:73799 * |
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 14, no. 3, 1979, pages 253 - 256 * |
FARMACO, EDIZIONE SCIENTIFICA, vol. 31, no. 3, 1976, pages 183 - 193 * |
FARMACO, EDIZIONE SCIENTIFICA, vol. 34, no. 12, 1979, pages 1005 - 1014 * |
FARMACO, EDIZIONE SCIENTIFICA, vol. 40, no. 3, 1985, pages 178 - 189 * |
FUKUTANI Y. ET AL: "Molecular structures of adducts of benzoyl isothiocyanate and hydrazones determines by the x-ray diffraction method", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 52, no. 8, 1979, pages 2223 - 2228, XP002997221 * |
GAZE. CHIM. ITAL., vol. 56, 1926, pages 695 - 700 * |
HANKOVSZKY H.O. ET AL: "Preparation of some omega-(pyridylakyl)benzamide and benzoate derivatives", JOURNAL OF MEDICINAL CHEMISTRY, vol. 9, no. 1, 1966, pages 151 - 153, XP002996395 * |
JOURNAL FUER PRAKTISCHE CHEMIE, vol. 38, no. 3-4, 1968, pages 150 - 161 * |
JOURNAL OF CHEMICAL RESEARCH, SYNOPSES, no. 4, 1977, pages 90 - 91 * |
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 14, no. 7, 1977, pages 1263 - 1265 * |
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 9, no. 1, 1972, pages 107 - 109 * |
JOURNAL OF ORGANIC CHEMISTRY, vol. 12, 1947, pages 446 - 455 * |
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 64, 1942, pages 2532 - 2537 * |
JOURNAL OF THE AMERICAN SOCIETY, vol. 85, 1963, pages 1278 - 1284 * |
JOURNAL OF THE CHEMICAL SOCIETY USECTION] C: ORGANIC, no. 22, 1971, pages 3769 - 3778 * |
KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII, no. 2, 1970, pages 155 - 158 * |
L'ABBE G. ET AL: "Trapping of thiaziridinimes with imines and nitriles", JOURNAL OF ORGANIC CHEMISTRY, vol. 41, no. 21, 1976, pages 3403 - 3406, XP002996400 * |
LEPPARD D. ET AL: "Methylation of 2-acylamido-1,3,4-thiadiazoles.An infrared, proton and carbon NMR study", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 17, no. 7, 1980, pages 1469 - 1472, XP002997219 * |
NATURWISSENSCHAFTEN, vol. 50, no. 21, 1963, pages 663 * |
ORGANIC MAGNETIC RESONANCE, vol. 14, no. 6, 1980, pages 515 - 516 * |
PHARMAZIE, vol. 24, no. 12, 1969, pages 728 - 730 * |
PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 108, no. 1-4, 1996, pages 203 - 220 * |
PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 156, 2000, pages 21 - 33 * |
PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 44, no. 3-4, 1989, pages 267 - 284 * |
PRAKTIKA TES AKADEMIAS ATHENON, vol. 53, no. A-D, 1979, pages 469 - 484 * |
PROCEEDINGS - INDIAN ACADEMY OF SCIENCES, SECTION A, vol. 18A, 1943, pages 108 - 112 * |
RENDICONTI - ISTITUTO LOMBARDO ACCADEMIA DI SCIENZE E LETTERE, A: SCIENZE MATEMATICHE, FISICHE, CHIMICHE E GEOLOGICHE, vol. 112, no. 1, 1979, pages 67 - 77 * |
ROBERT J.M.H. ET AL: "Nonacidic antiinflammatory compounds. II. Synthesis and activity of 6-amino-2,4-lutidine derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 11, 1994, pages 841 - 854, XP002996390 * |
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, vol. 38, no. 7, 2002, pages 1030 - 1034 * |
TETRAHEDRON, vol. 19, 1963, pages 357 - 372 * |
YAKUGAKU ZASSHI, vol. 81, 1961, pages 1378 - 1380 * |
ZHURNAL FIZICHESKOI KHIMII, vol. 31, 1957, pages 1745 - 1755 * |
ZHURNAL FIZICHESKOI KHIMII, vol. 33, 1959, pages 2096 - 2109 * |
ZHURNAL PRIKLADNOI KHIMII, vol. 13, 1940, pages 1215 - 1219 * |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7910613B2 (en) | 2004-09-22 | 2011-03-22 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
WO2006114093A1 (en) * | 2005-04-25 | 2006-11-02 | H. Lundbeck A/S | Pro-drugs of n-thiazol-2yl-benzamide derivatives |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140385A3 (en) * | 2006-05-31 | 2008-02-07 | Abbott Lab | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
US9006275B2 (en) | 2006-05-31 | 2015-04-14 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140439A3 (en) * | 2006-05-31 | 2008-01-24 | Abbott Lab | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140439A2 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
US7875639B2 (en) | 2006-05-31 | 2011-01-25 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
US8546583B2 (en) | 2006-05-31 | 2013-10-01 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140385A2 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
JP2009538933A (ja) * | 2006-05-31 | 2009-11-12 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての化合物およびその使用 |
JP2009538931A (ja) * | 2006-05-31 | 2009-11-12 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしてのチアゾール化合物およびそれの使用 |
US7868038B2 (en) | 2006-08-31 | 2011-01-11 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US7985768B2 (en) | 2006-08-31 | 2011-07-26 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8598224B2 (en) | 2006-08-31 | 2013-12-03 | Abbvie Inc. | Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands |
WO2008029825A1 (fr) | 2006-09-05 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Dérivé d'imidazole |
US8236841B2 (en) | 2006-09-13 | 2012-08-07 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocycle derivative |
WO2008032764A1 (fr) | 2006-09-13 | 2008-03-20 | Kyowa Hakko Kirin Co., Ltd. | Dérivé hétérocyclique fusionné |
US8865753B2 (en) | 2007-03-28 | 2014-10-21 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
WO2008121558A1 (en) * | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7875640B2 (en) | 2007-03-28 | 2011-01-25 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8835475B2 (en) | 2007-04-17 | 2014-09-16 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
WO2008130953A2 (en) * | 2007-04-17 | 2008-10-30 | Abbott Laboratories | 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2008130953A3 (en) * | 2007-04-17 | 2008-12-11 | Abbott Lab | 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands |
US8501794B2 (en) | 2007-04-17 | 2013-08-06 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
WO2008144360A1 (en) | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
US8735434B2 (en) | 2007-05-18 | 2014-05-27 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) * | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
JP2011500579A (ja) * | 2007-10-12 | 2011-01-06 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規化合物 |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8044071B2 (en) | 2007-10-18 | 2011-10-25 | Abbott Laboratories | Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist |
JP2011504186A (ja) * | 2007-11-21 | 2011-02-03 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物およびその使用 |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
JP2011513495A (ja) * | 2008-03-11 | 2011-04-28 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US8338467B2 (en) | 2008-03-11 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8466290B2 (en) | 2008-07-10 | 2013-06-18 | Pharma Ip General Incorporated Association | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
WO2010004761A1 (ja) * | 2008-07-10 | 2010-01-14 | 一般社団法人ファルマIp | キノリンカルボキサミド誘導体を有効成分とするstat3阻害剤 |
EA021306B1 (ru) * | 2008-07-10 | 2015-05-29 | ФАРМА АйПи ДЖЕНЕРАЛ ИНКОРПОРЕЙТЕД АССОШИЭЙШН | Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента |
AU2009269410B2 (en) * | 2008-07-10 | 2013-12-05 | General Incorporated Association Pharma Valley Project Supporting Organisation | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
CN102099352B (zh) * | 2008-07-10 | 2014-02-26 | 一般社团法人创药分子Ip | 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂 |
US8173687B2 (en) | 2008-08-15 | 2012-05-08 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8188135B2 (en) | 2008-09-16 | 2012-05-29 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8859596B2 (en) | 2008-09-16 | 2014-10-14 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8895592B2 (en) | 2008-12-16 | 2014-11-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8288428B2 (en) | 2009-03-27 | 2012-10-16 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US20100249087A1 (en) * | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US20110144165A1 (en) * | 2009-12-16 | 2011-06-16 | Abbott Laboratories | Prodrug compounds useful as cannabinoid ligands |
US8536336B2 (en) * | 2009-12-16 | 2013-09-17 | Abbvie Inc. | Prodrug compounds useful as cannabinoid ligands |
US8586596B2 (en) | 2010-06-15 | 2013-11-19 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US9883673B2 (en) | 2011-08-26 | 2018-02-06 | Meiji Seika Pharma Co., Ltd. | Method for producing pest control agent |
US9357776B2 (en) | 2011-08-26 | 2016-06-07 | Meiji Seika Pharma Co., Ltd. | Method for producing pest control agent |
JPWO2013031671A1 (ja) * | 2011-08-26 | 2015-03-23 | Meiji Seikaファルマ株式会社 | 有害生物防除剤の製造法 |
WO2013031671A1 (ja) * | 2011-08-26 | 2013-03-07 | Meiji Seikaファルマ株式会社 | 有害生物防除剤の製造法 |
JP2017125026A (ja) * | 2011-08-26 | 2017-07-20 | Meiji Seikaファルマ株式会社 | 有害生物防除剤の製造法 |
AP3749A (en) * | 2011-08-26 | 2016-07-31 | Meiji Seika Pharma Co Ltd | Method for producing pest controlling agent |
CN110256336A (zh) * | 2012-02-29 | 2019-09-20 | 明治制果药业株式会社 | 具有2-亚氨基的含氮杂环衍生物以及包含它的害虫防治剂 |
WO2013129692A2 (en) | 2012-02-29 | 2013-09-06 | Meiji Seika Pharma Co., Ltd. | Nitrogen-containing heterocyclic derivative having 2-imino group and pest control agent including the same |
EP2634174A2 (en) | 2012-02-29 | 2013-09-04 | Meiji Seika Pharma Co., Ltd. | Nitrogen-containing hetercyclic derivate having 2-imino group and pest control agent including the same |
JP2015511577A (ja) * | 2012-02-29 | 2015-04-20 | Meiji Seikaファルマ株式会社 | 2−イミノ基を有する含窒素ヘテロ環誘導体及びそれを含んでなる有害生物防除剤 |
US9650369B2 (en) * | 2012-09-28 | 2017-05-16 | Xavier University Of Louisiana | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease |
US20150274714A1 (en) * | 2012-09-28 | 2015-10-01 | Xavier University Of Louisiana | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease |
US20160227777A1 (en) * | 2013-09-19 | 2016-08-11 | Basf Se | N-Acylimino Heterocyclic Compounds |
US10206397B2 (en) * | 2013-09-19 | 2019-02-19 | Basf Se | N-acylimino heterocyclic compounds |
US10757938B2 (en) | 2013-09-19 | 2020-09-01 | Basf Se | N-acylimino Heterocyclic Compounds |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
WO2024024961A1 (ja) * | 2022-07-29 | 2024-02-01 | 住友ファーマ株式会社 | 2(1h)-ピリジンイミン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
US20080312435A1 (en) | 2008-12-18 |
AU2005303223A1 (en) | 2006-05-18 |
RU2007122351A (ru) | 2008-12-20 |
CA2587667A1 (en) | 2006-05-18 |
JPWO2006051704A1 (ja) | 2008-05-29 |
EP1820504A1 (en) | 2007-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006051704A1 (ja) | イミン化合物 | |
CN102153562B (zh) | 螺-吲哚酮化合物及其作为治疗剂的用途 | |
TWI605040B (zh) | 作為mGluR2負向異位性調節劑之喹啉甲醯胺及喹啉甲腈衍生物、組合物及其用途 | |
CA3018185C (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
US7514441B2 (en) | Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents | |
EA025529B1 (ru) | Циклопропанаминовое соединение | |
JP6552061B2 (ja) | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用 | |
WO2007032466A1 (ja) | 複素環化合物、その製造方法並びに用途 | |
JP2018517731A (ja) | Nrf2レギュレーター | |
WO2008104077A1 (en) | Small molecule inhibitors of protein arginine methyltransferases (prmts) | |
CA2770712A1 (en) | Heterocyclic compounds as janus kinase inhibitors | |
WO2007055418A1 (ja) | アザ置換スピロ誘導体 | |
US20090264455A9 (en) | Androgen Receptor Modulator Compounds and Methods | |
CA2870062A1 (en) | Pyrrolopyrazone inhibitors of tankyrase | |
TW201439090A (zh) | 咪唑並吡啶化合物 | |
EP1836200A1 (en) | Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof | |
WO2009085256A1 (en) | Anti-hiv compounds | |
AU2013214226A1 (en) | Fused pyrroledicarboxamides and their use as pharmaceuticals | |
WO2008076562A1 (en) | 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists | |
JP2010517967A (ja) | 摂食障害の治療のための1−オキサ−3−アザスピロ[4,5]デカン−2−オン誘導体 | |
WO2014146246A1 (en) | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors | |
US20060234997A1 (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
DK2616460T3 (en) | HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISEASES CAUSED BY decreased neurotransmission of serotonin, norepinephrine or dopamine | |
CA3158731A1 (en) | Adenosine receptor antagonist compounds | |
CN109890826A (zh) | 一种含有氮杂环螺旋结构的高效ido/tdo双抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006544838 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2587667 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580039005.4 Country of ref document: CN Ref document number: 11667728 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4177/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005800461 Country of ref document: EP Ref document number: 2005303223 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2007122351 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2005303223 Country of ref document: AU Date of ref document: 20051031 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005303223 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005800461 Country of ref document: EP |